• FDA Expands Indication for PROGRAF® for Lung Transplant Recipients americanpharmaceuticalreview
    July 22, 2021
    Astellas Pharma Inc. announced that the U.S. FDA approved its supplemental New Drug Application (sNDA) for PROGRAF® (tacrolimus) for the prevention of organ rejection in adult and pediatric lung transplant recipients.
  • Elevated Risk for Lung CA in Lung Transplant Recipients Explored drugs
    December 28, 2018
PharmaSources Customer Service